Ultomiris EU approval : Alexion Pharmaceuticals has secured approval from the European Commission (EC) for its C5 complement inhibitor Ultomiris (ravulizumab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults. The Ultomiris EU approval is for patients with PNH with hemolysis with clinical symptoms that indicate high disease activity, and also for adult patients […]
Alexion Pharmaceuticals has secured a significant milestone with the FDA granting priority review for its C5 complement inhibitor, SOLIRIS (eculizumab), as a treatment for neuromyelitis optica spectrum disorder (NMOSD) in patients who test positive for anti-aquaporin-4 (AQP4) autoantibodies. This critical approval comes as part of a supplemental Biologics License Application (sBLA), which has been accepted […]
In a significant move within the pharmaceutical industry, Alexion Pharmaceuticals, a leading global biopharma company, has announced its acquisition of Syntimmune, a Boston-based clinical-stage biotech firm. The deal, valued at approximately $1.2 billion, marks a strategic expansion for Alexion as it looks to bolster its portfolio of treatments for rare diseases. Under the terms of […]
In a significant move to expand its rare disease drug portfolio, U.S.-based Alexion Pharmaceuticals has announced an all-cash acquisition of Swedish pharmaceutical company Wilson Therapeutics for SEK7.1 billion ($855 million). This strategic acquisition is set to significantly bolster Alexion’s offerings in the rare disease sector, particularly in treating Wilson disease, a rare copper-mediated disorder. Details […]